MiNK Therapeutics, Inc. (INKT) Stock: Climbs on Encouraging Phase 2 Data for agenT-797 in Severe Pneumonia

TLDR

Table of Contents

MiNK Therapeutics stock moves after Phase 2 pneumonia trial update.
agenT-797 shows early gains in oxygenation and infection control.
Data presented at 2026 Military Health System Research Symposium event.
Patients treated in Ukraine show no major adverse events reported.
MiNK Therapeutics advances off-the-shelf iNKT therapy for lung injury.

INKT shares traded at $11.48 after the company released new clinical updates. The stock reflected a $0.22 decline, or 1.88%, during Thursday’s session. MiNK Therapeutics announced initial results from its Phase 2 study evaluating agenT-797 in severe hypoxemic pneumonia.

MiNK Therapeutics, Inc., INKT

Trial Data Reveals Early Clinical Progress

MiNK Therapeutics presented the findings at the 2026 Military Health System Research Symposium, and Dr. Terese Hammond led the presentation. Researchers from First Lviv Territorial Medical Union in Ukraine co-authored the data alongside MiNK Therapeutics. Severe lung injury carries high mortality, and no approved therapy currently reduces it effectively.

Multidrug-resistant infections often worsen outcomes in conflict zones, so traditional antibiotics frequently fail. agenT-797 aims to restore barrier immunity and limit inflammatory lung damage in these settings. Patients treated with agenT-797 remained alive through Day 28, and their hemodynamics improved noticeably.

Oxygenation levels rose alongside mental status improvements among the treated group. Microbiological testing confirmed control of baseline infections in these critically ill patients. Blood and lung fluid analyses also showed reduced inflammatory markers following treatment with agenT-797.

Physician and Executive Commentary Highlight Results

Dr. Hammond stated that patients entered the study facing severe respiratory failure and substantial medical risk. She noted encouraging improvements in oxygenation, infection control, and markers tied to inflammation reduction. The biological changes also aligned with earlier findings MiNK Therapeutics presented at ASGCT and ATS conferences.

Jennifer Buell, President and CEO of MiNK Therapeutics, emphasized the trial’s rapid execution timeline. She said the team activated the randomized trial and dosed the first patient within days of approval. Buell added that Day 28 observations followed weeks later, despite the active conflict environment surrounding the site.

Buell highlighted the value of an off-the-shelf therapy that skips patient-specific manufacturing steps. She noted the treatment avoids HLA matching and lymphodepletion, unlike many competing cell therapies. MiNK Therapeutics said it remains focused on supporting medical readiness for service members and critically ill patients.

Company Background Supports Pipeline Direction

MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies for cancer and immune-related disorders. The company positions agenT-797 as a scalable option for austere and resource-limited medical environments. No major serious adverse events tied to agenT-797 emerged among the initial treated patients.

MiNK Therapeutics continues advancing this program following the Phase 2 update. The company plans further data disclosures as enrollment and treatment progress across sites. MiNK Therapeutics remains focused on expanding its iNKT-cell platform across additional disease indications going forward.

✨ Limited Time Offer